SAN FRANCISCO, April 18, 2018 /PRNewswire/ -- Kindred
Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company
focused on saving and improving the lives of pets, today announced
that it will release its first quarter 2018 financial results on
May 8, 2018 after the market close.
The Company will host a conference call at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time that day.
Interested parties may access the call by dialing toll-free
(855) 433-0927 from the US, or (484) 756-4262 internationally, and
using conference ID 8967967.
The call will also be webcast live at
https://edge.media-server.com/m6/p/nhw6xeop.
A replay will also be available at that link for 30 days.
About Kindred Biosciences
Kindred Biosciences is a pre-commercialization stage
biopharmaceutical company focused on saving and improving the lives
of pets. Its mission is to bring to pets the same kinds of
safe and effective medicines that human family members enjoy.
The Company's strategy is to identify compounds and targets
that have already demonstrated safety and efficacy in humans and to
develop therapeutics based on these validated compounds and targets
for dogs, cats and horses. The Company has a deep pipeline of
novel drugs and biologics in development across many therapeutic
classes.
For more information or to download the corporate presentation,
visit www.KindredBio.com/LearnMore. Stay connected with KindredBio
on Facebook at www.Facebook.com/KindredBio.
Contact
Russell Radefeld
KindredBio
russell.radefeld@kindredbio.com
(650) 701-7904
View original content with
multimedia:http://www.prnewswire.com/news-releases/kindred-biosciences-to-announce-first-quarter-2018-financial-results-300632389.html
SOURCE Kindred Biosciences, Inc.